Shire paying $260M+ up front for Lumena Pharmaceuticals
By Cormac Sheridan
Tuesday, May 13, 2014
DUBLIN Investors in Lumena Pharmaceuticals Inc. are in line for a big payday, as Shire plc is buying the San Diego-based drug developer for $260 million up front, plus undisclosed milestones linked to the results of clinical trials of one of its pipeline assets and whatever cash it has left on its balance sheet when the transaction closes.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.